Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome
Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome
复制标题
肿瘤浸润 CD103 细胞的普遍存在可识别临床结果较差的治疗敏感前列腺癌
DOI:
10.1038/s41416-023-02183-4
复制
发表时间:
2023-02-09
影响因子:
8.8
通讯作者:
Jiang, Haowen
中科院分区:
文献类型:
--
作者:
Zhou, Quan;Ou, Yuxi;Jiang, Haowen
BACKGROUND: The clinical significance and immune correlation of CD103(+) cells in prostate cancer (PCa) remain explored.METHODS: In total, 1080 patients with PCa underwent radical prostatectomy from three cohorts were enrolled for retrospective analysis. Tumour microarrays were constructed and fresh tumour samples were analysed by flow cytometry.RESULTS: High CD103(+) cell infiltration correlated with reduced biochemical recurrence (BCR)-free survival in PCa. Adjuvant hormone therapy (HT) prolonged the BCR-free survival for high-risk node-negative diseases with CD103(+) cell abundance. CD103(+) cell infiltration correlated with less cytotoxic expression and increased infiltration of CD8(+) and CD4(+) T cells, M1 macrophages and mast cells in PCa. Intratumoral CD8(+) T cell was the predominant source of CD103, and the CD103+ subset of CD8(+) T cells was featured with high IL-10, PD-1 and CTLA-4 expression. Tumour-infiltrating CD103(+) CD8(+) T cells exerted anti-tumour function when treated with HT ex vivo.DISCUSSION: CD103(+) cell infiltration predicted BCR-free survival and response to adjuvant HT in PCa. CD103(+) cell infiltration correlated with an enriched but immune-evasive immune landscape. The study supported a model that CD103 expression conferred negative prognostic impact and immunosuppressive function to tumour-infiltrating CD8(+) T cells, while the CD103(+) CD8(+) T cells exhibited a powerful anti-tumour immunity with response to HT.